Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy.
Osmol Therapeutics has raised $5.2M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Osmol Therapeutics's investors include Koax Investment Partners.
Osmol Therapeutics is headquartered in New Haven, United States.
Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy.
Osmol Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Osmol Therapeutics — Funding & Investors." VCBacked, April 12, 2022, https://www.vcbacked.co/company/osmol-therapeutics. Accessed October 1, 2026.
VCBacked. (2022). Osmol Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/osmol-therapeutics
{{cite web |title=Osmol Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/osmol-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated